Edgestream Partners L.P. Sells 30,904 Shares of DexCom, Inc. $DXCM

Edgestream Partners L.P. lessened its holdings in DexCom, Inc. (NASDAQ:DXCM) by 66.4% in the 1st quarter, HoldingsChannel.com reports. The firm owned 15,622 shares of the medical device company’s stock after selling 30,904 shares during the quarter. Edgestream Partners L.P.’s holdings in DexCom were worth $981,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Norges Bank bought a new stake in shares of DexCom in the 4th quarter valued at approximately $483,356,000. AQR Capital Management LLC lifted its position in shares of DexCom by 597.8% during the 4th quarter. AQR Capital Management LLC now owns 3,102,789 shares of the medical device company’s stock worth $205,932,000 after buying an additional 2,658,158 shares during the period. Employees Provident Fund Board bought a new position in shares of DexCom during the 4th quarter worth approximately $145,352,000. J. Stern & Co. LLP boosted its stake in DexCom by 2,114.8% in the 4th quarter. J. Stern & Co. LLP now owns 1,601,973 shares of the medical device company’s stock valued at $106,323,000 after buying an additional 1,529,641 shares in the last quarter. Finally, SG Americas Securities LLC boosted its stake in DexCom by 271.4% in the 1st quarter. SG Americas Securities LLC now owns 2,065,277 shares of the medical device company’s stock valued at $129,699,000 after buying an additional 1,509,219 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

Insiders Place Their Bets

In other news, Director Mark G. Foletta sold 2,000 shares of the firm’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $85.32, for a total value of $170,640.00. Following the completion of the sale, the director directly owned 48,852 shares in the company, valued at approximately $4,168,052.64. This trade represents a 3.93% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,756 shares of DexCom stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $76.32, for a total value of $2,042,017.92. Following the completion of the transaction, the insider directly owned 328,970 shares of the company’s stock, valued at $25,106,990.40. This represents a 7.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 102,506 shares of company stock valued at $7,535,898. 0.28% of the stock is owned by corporate insiders.

DexCom Stock Down 0.4%

NASDAQ DXCM opened at $86.94 on Wednesday. The stock’s 50 day simple moving average is $73.74 and its 200 day simple moving average is $69.43. DexCom, Inc. has a one year low of $54.11 and a one year high of $87.85. The firm has a market cap of $32.81 billion, a PE ratio of 34.36, a price-to-earnings-growth ratio of 1.48 and a beta of 1.41. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.73 and a quick ratio of 1.43.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.61 by $0.09. The firm had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.29 billion. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The business’s revenue for the quarter was up 13.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.48 EPS. As a group, sell-side analysts forecast that DexCom, Inc. will post 2.64 earnings per share for the current fiscal year.

DexCom News Roundup

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Argus raised its price target to $96 from $86 and maintained a “buy” rating, implying approximately 10% potential upside from the referenced price. Benzinga
• Positive Sentiment: DexCom’s latest quarterly results exceeded expectations, with adjusted earnings of $0.70 per share versus a $0.61 consensus estimate and revenue of $1.31 billion versus $1.29 billion expected. Revenue increased 13.1% year over year, while operating income reportedly grew 49.7%; management also raised its fiscal-year 2026 guidance. DexCom: Still A Cautious Buy Following Earnings
• Positive Sentiment: Growth catalysts include adoption of the G7 glucose-monitoring system, international expansion and the “Road to 100” initiative aimed at broadening diabetes coverage. Margin improvement, share repurchases and a solid balance sheet further support the investment case. DexCom: Still A Cautious Buy Following Earnings
• Positive Sentiment: Technical momentum has improved: DXCM moved above its 20-day moving average and reached a new 52-week high, signaling continued short-term buying interest. DexCom 52-Week High
• Neutral Sentiment: Analyst opinion remains broadly constructive, with another reported price-target increase to $82; however, targets vary significantly. At roughly 34 times earnings, valuation leaves the stock sensitive to any slowdown in growth or weaker guidance. DexCom Price Target Raised
• Negative Sentiment: Director Mark G. Foletta sold a combined 4,000 shares for approximately $330,640 under a pre-arranged Rule 10b5-1 plan. Because the sales were scheduled in advance and he retains a substantial position, the transactions are a limited negative signal rather than clear evidence of declining confidence. SEC Insider Trading Filing

Analysts Set New Price Targets

Several research analysts have issued reports on the company. BTIG Research reiterated a “buy” rating and set a $90.00 price objective (up from $80.00) on shares of DexCom in a research note on Friday. Weiss Ratings downgraded shares of DexCom from a “hold (c)” rating to a “hold (c-)” rating in a research note on Tuesday, July 28th. Argus upped their target price on shares of DexCom from $86.00 to $96.00 and gave the stock a “buy” rating in a report on Tuesday. JPMorgan Chase & Co. upped their target price on shares of DexCom from $65.00 to $82.00 and gave the stock a “neutral” rating in a report on Friday, July 31st. Finally, Piper Sandler reiterated an “overweight” rating and set a $95.00 target price (up from $88.00) on shares of DexCom in a research report on Friday. Two analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, DexCom presently has a consensus rating of “Moderate Buy” and an average price target of $88.71.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.